Obsessive-compulsive disorder (OCD)
Conditions
Brief summary
Difference in the total score of the Y-BOCS scale between baseline (V1; before intervention with the investigational drug) and week 16 (V9; after intervention with the investigational drug), between the different groups treated with different doses of pramipexole.
Detailed description
Number of adverse events observed (nonserious, serious not related to the investigational medicinal product, and serious related to the investigational medicinal product) from day 2 (V1; after the first dose of the investigational medicinal product) to the week 24 (V11; end of study) in the different pramipexole treatment groups.
Interventions
Sponsors
CCAB Centro Clinico Academico Braga Associacao
Eligibility
Sex/Gender
All
Age
18 Years to 64 Years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Difference in the total score of the Y-BOCS scale between baseline (V1; before intervention with the investigational drug) and week 16 (V9; after intervention with the investigational drug), between the different groups treated with different doses of pramipexole. | — |
Secondary
| Measure | Time frame |
|---|---|
| Number of adverse events observed (nonserious, serious not related to the investigational medicinal product, and serious related to the investigational medicinal product) from day 2 (V1; after the first dose of the investigational medicinal product) to the week 24 (V11; end of study) in the different pramipexole treatment groups. | — |
Countries
Portugal
Outcome results
None listed